Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II

Diabetes treatment cost represents an ever-growing problem. The adoption of new drugs in therapy, although they can guarantee an improvement in patient’s quality of life, can meet obstacles when it involves an increase in costs. We decided to compare the costs and benefits of the new saxagliptin and...

Descripción completa

Detalles Bibliográficos
Autores principales: Torre, Enrico, Bruno, Giacomo Matteo, Di Matteo, Sergio, Martinotti, Chiara, Valentino, Maria Chiara, Bottaro, Luigi Carlo, Colombo, Giorgio Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298424/
https://www.ncbi.nlm.nih.gov/pubmed/32595277
http://dx.doi.org/10.1177/1178632920929982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298424/
https://www.ncbi.nlm.nih.gov/pubmed/32595277
http://dx.doi.org/10.1177/1178632920929982

Ejemplares similares